The global healthcare contract manufacturing outsourcing market size was valued at USD 221.88 billion in 2025 and is projected to grow from USD 243.47 billion in 2026 to USD 511.74 billion by 2034, registering a CAGR of 9.73% during the forecast period from 2026 to 2034. Asia Pacific dominated the healthcare contract manufacturing outsourcing market with a market share of 42.5% in 2025.
Healthcare contract manufacturing outsourcing refers to the practice of pharmaceutical, biotechnology, and medical device companies partnering with specialized third-party manufacturers to produce drugs, medical devices, biologics, and related healthcare products. This approach helps reduce production costs, improve operational efficiency, ensure regulatory compliance, and accelerate product commercialization. Growth is supported by increasing demand for specialized manufacturing capabilities, expanding pharmaceutical pipelines, and rising investments in advanced production technologies.
Download a Free Sample To learn more about this report,
Increasing Outsourcing of Specialized Pharmaceutical Manufacturing
Healthcare companies are increasingly using contract manufacturers for specialized production activities that require dedicated facilities, technical expertise, and established quality systems. Outsourcing allows pharmaceutical and biotechnology companies to access manufacturing capabilities without developing equivalent internal infrastructure, particularly for complex formulations, sterile products, and specialized production processes.
In August 2025, the U.S. Food and Drug Administration launched the FDA PreCheck initiative to facilitate the development of pharmaceutical manufacturing capacity and strengthen manufacturing supply chains, highlighting the increasing importance of specialized production infrastructure.
Growing Adoption of Flexible Manufacturing for Biopharmaceutical Products
Contract manufacturers are increasingly developing flexible production capabilities that can accommodate multiple biopharmaceutical modalities and changing client requirements. Flexible facilities can support smaller production runs, technology transfers, process development, and manufacturing scale-up as products progress through clinical development and commercialization. This is increasing the value of outsourcing partners beyond basic production services.
In September 2025, the U.S. Food and Drug Administration held a public meeting on domestic manufacturing of drugs and biological products, highlighting the need for manufacturing capabilities that can support emerging pharmaceutical and biotechnology products.
Increasing Complexity of Healthcare Product Manufacturing
Developing all required capabilities internally can be costly and time-consuming, encouraging healthcare companies to use external manufacturers with established technical infrastructure. Manufacturing complexity therefore supports continued demand for contract outsourcing.
In January 2025, the U.S. Food and Drug Administration's medical-device guidance continued to recognize contract manufacturers as an established component of device production, including manufacturing, sterilization, and packaging activities.
Loss of Direct Manufacturing Control Can Limit Outsourcing Decisions
Outsourcing production can reduce a healthcare company's direct control over manufacturing schedules, process changes, quality systems, and production priorities. Dependence on an external supplier can also create coordination requirements between the contract manufacturer and the sponsoring company. These considerations can discourage outsourcing when companies view internal production control as strategically important.
In March 2025, FDA guidance for active pharmaceutical ingredient manufacturing continued to require companies to evaluate contractors for GMP compliance and establish formal agreements defining manufacturing and quality responsibilities.
Expansion of Domestic Manufacturing Creates New Outsourcing Capacity
Efforts to strengthen domestic healthcare-product supply chains are creating opportunities for contract manufacturers to establish or expand production facilities closer to pharmaceutical and medical-device customers. Domestic outsourcing can reduce dependence on distant manufacturing networks while providing healthcare companies with access to qualified external capacity. Investment in local production infrastructure can therefore create additional outsourcing opportunities.
In September 2025, the FDA reported that approximately 53% of brand drug products and 69% of generic drug products distributed in the United States were manufactured outside the country, supporting policy efforts to expand domestic pharmaceutical manufacturing capacity.
Maintaining Consistent Quality Across Outsourced Production Networks
Contract manufacturing can involve multiple facilities, suppliers, laboratories, sterilization providers, and other external partners. Maintaining consistent quality across these interconnected operations requires effective auditing, documentation, change control, traceability, and communication. Failure to coordinate these activities can create regulatory and product-quality risks for both the contract manufacturer and healthcare company.
In March 2026, the FDA issued a warning letter to a registered outsourcing facility after identifying serious manufacturing deficiencies during an inspection, demonstrating the continuing quality-control risks associated with outsourced healthcare-product production.
Pharmaceutical Contract Manufacturing Services Segment Dominated the Market with 61.4% Share in 2025
The pharmaceutical contract manufacturing services segment dominated the global Healthcare Contract Manufacturing Outsourcing Market with a 61.4% share in 2025, driven by increasing outsourcing of drug production, rising demand for cost-efficient manufacturing, and the growing complexity of pharmaceutical products. Pharmaceutical companies continue to rely on contract manufacturers to improve production capacity, accelerate product launches, and comply with stringent regulatory requirements.
The medical device contract manufacturing services segment is witnessing steady growth as medical device companies increasingly outsource manufacturing activities to reduce operational costs and gain access to advanced production technologies. Rising demand for precision-engineered devices, minimally invasive products, and technologically advanced healthcare equipment continues to support the expansion of this segment.
The growing need for flexible manufacturing capabilities, global supply chain optimization, and specialized production expertise is further encouraging healthcare companies to expand outsourcing partnerships. Continuous investments in automation and quality assurance are also strengthening the long-term growth of contract manufacturing services.
Active Pharmaceutical Ingredients (API) Manufacturing Segment Dominated the Market with 44.2% Share in 2025
The active pharmaceutical ingredients (API) manufacturing segment dominated the pharmaceutical contract manufacturing services market with a 44.2% share in 2025, supported by increasing demand for high-quality APIs across branded and generic medicines. Pharmaceutical companies are increasingly outsourcing API production to improve manufacturing efficiency, ensure regulatory compliance, and optimize production costs.
The formulations manufacturing and packaging services segments are expanding steadily as drug manufacturers focus on improving production scalability and product presentation. Growing demand for tablets, capsules, injectables, and other finished dosage forms, along with the need for innovative and compliant packaging solutions, continues to drive outsourcing activities across both segments.
Rising biologics production, personalized medicine development, and stricter packaging regulations are expected to create additional opportunities for formulation manufacturing and packaging service providers. Continuous investments in advanced manufacturing technologies are further supporting growth across these segments.
Device Manufacturing Segment Dominated the Market with 38.8% Share in 2025
The device manufacturing segment dominated the medical device contract manufacturing services market with a 38.8% share in 2025, driven by increasing production of diagnostic devices, surgical instruments, implantable devices, and patient monitoring equipment. Growing demand for high-quality medical devices and compliance with international quality standards continue to strengthen the segment's leading position.
The assembly manufacturing and accessories manufacturing segments are witnessing steady growth as manufacturers increasingly outsource component assembly and accessory production to improve operational efficiency and reduce manufacturing costs. Rising demand for complex medical devices requiring precision assembly is further supporting these segments.
The design outsourcing segment is projected to grow steadily as medical device companies seek specialized expertise for product design, engineering, prototyping, and regulatory documentation. Increasing innovation in connected medical devices, wearable technologies, and minimally invasive products continues to drive demand for outsourced design services.
Pharmaceutical & Biopharmaceutical Companies Segment Dominated the Market with 58.4% Share in 2025
The pharmaceutical and biopharmaceutical companies segment dominated the global Healthcare Contract Manufacturing Outsourcing Market with a 58.4% share in 2025, supported by rising investments in drug development, biologics manufacturing, and large-scale commercial production.
The medical device companies and others segments are witnessing steady growth as manufacturers expand outsourcing partnerships to support product innovation, regulatory compliance, and cost-effective production. Growing demand for advanced medical devices, diagnostics, and specialized healthcare products is contributing to the expansion of both segments.
Increasing healthcare investments, expanding production capacity, and the need for specialized manufacturing expertise are expected to create long-term growth opportunities across all end-user categories. Continued collaboration between healthcare companies and contract manufacturing organizations remains a key factor supporting market expansion.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
North America healthcare contract manufacturing outsourcing market accounted for 29.8% of the global market, reaching USD 66.12 billion in 2025, and is projected to grow at a CAGR of 9.48% during the forecast period. Rising demand for outsourced pharmaceutical and medical device manufacturing, increasing biologics production, and growing investments in advanced manufacturing technologies continue to drive regional market growth. Strong regulatory standards and expanding research activities further support market expansion.
The U.S. market was valued at USD 56.20 billion in 2025, making it the largest contributor in North America. Growing demand for biologics, increasing outsourcing by pharmaceutical companies, and expanding investments in advanced manufacturing facilities continue to strengthen market growth.
Canada's market reached USD 9.92 billion in 2025. Expanding pharmaceutical production, increasing clinical research activities, and rising investments in biotechnology manufacturing continue to support steady market expansion.
Europe healthcare contract manufacturing outsourcing market accounted for 20.4% of the global market, reaching USD 45.26 billion in 2025, and is expected to register a CAGR of 8.21% during the forecast period. Increasing pharmaceutical outsourcing, growing demand for specialized manufacturing services, and continuous investments in biologics and medical device production are driving regional growth. Supportive regulatory frameworks also contribute to market development.
Germany's market accounted for USD 13.13 billion in 2025. The country's strong pharmaceutical manufacturing base, expanding biologics production, and increasing adoption of contract manufacturing services continue to support market growth.
The UK market was valued at USD 9.05 billion in 2025. Rising investments in life sciences, growing demand for contract development and manufacturing services, and expanding clinical research activities continue to contribute to market expansion.
Asia Pacific healthcare contract manufacturing outsourcing market accounted for 42.5% of the global market, valued at USD 94.30 billion in 2025, and is projected to register a CAGR of 8.92% during the forecast period. Cost-effective manufacturing, expanding pharmaceutical production, increasing medical device exports, and growing investments in biotechnology continue to accelerate regional market growth. The region also benefits from a large skilled workforce and supportive government initiatives.
Japan's market generated USD 16.97 billion in 2025. Rising demand for high-quality pharmaceutical manufacturing, increasing biologics production, and continued investments in advanced healthcare technologies continue to support market growth.
China's market accounted for USD 47.15 billion in 2025, representing the largest share within Asia Pacific. Expanding pharmaceutical manufacturing capacity, strong medical device production, competitive manufacturing costs, and increasing global outsourcing contracts continue to drive market expansion.
Latin America healthcare contract manufacturing outsourcing market accounted for 4.2% of the global market, reaching USD 9.32 billion in 2025, and is projected to grow at a CAGR of 7.76% during the forecast period. Growing pharmaceutical production, increasing healthcare investments, and rising demand for outsourced manufacturing services continue to support regional market growth.
Brazil's market reached USD 4.75 billion in 2025. Expanding pharmaceutical manufacturing, increasing investments in healthcare infrastructure, and growing demand for contract manufacturing services continue to create growth opportunities across the country.
Middle East & Africa healthcare contract manufacturing outsourcing market accounted for 3.1% of the global market, totaling USD 6.88 billion in 2025, and is anticipated to grow at a CAGR of 7.18% during the forecast period. Increasing healthcare investments, expanding pharmaceutical manufacturing capabilities, and growing focus on local production are supporting regional market growth.
The UAE market was valued at USD 2.48 billion in 2025. Rising investments in pharmaceutical manufacturing, expanding biotechnology initiatives, and government efforts to strengthen domestic healthcare production continue to drive market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Real World Evidence Solutions Market Size, Share, 2034
Surrogacy Market Size, Share, Growth, Analysis, Report, 2034
Viral Vector Manufacturing Market Size, Share, Growth, Analysis, 2034
Healthcare Staffing Market Size, Share, Growth, Analysis, 2034
Health Insurance Market Size, Share, Growth, Forecast, 2034
Central lab market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com